Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1432-0584
Extent
Online-Ressource
Language
Englisch
Notes
online resource.

Bibliographic citation
Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma ; volume:101 ; number:5 ; day:4 ; month:3 ; year:2022 ; pages:979-989 ; date:5.2022
Annals of hematology ; 101, Heft 5 (4.3.2022), 979-989, 5.2022

Creator
Murayama, Kayoko
Kiguchi, Toru
Izutsu, Koji
Kameoka, Yoshihiro
Hidaka, Michihiro
Kato, Harumi
Rai, Shinya
Kuroda, Junya
Ishizawa, Kenichi
Ichikawa, Satoshi
Ando, Kiyoshi
Ogura, Michinori
Fukushima, Koji
Terui, Yasuhito
Contributor
SpringerLink (Online service)

DOI
10.1007/s00277-022-04801-2
URN
urn:nbn:de:101:1-2022062521025408847695
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
15.08.2025, 7:29 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Murayama, Kayoko
  • Kiguchi, Toru
  • Izutsu, Koji
  • Kameoka, Yoshihiro
  • Hidaka, Michihiro
  • Kato, Harumi
  • Rai, Shinya
  • Kuroda, Junya
  • Ishizawa, Kenichi
  • Ichikawa, Satoshi
  • Ando, Kiyoshi
  • Ogura, Michinori
  • Fukushima, Koji
  • Terui, Yasuhito
  • SpringerLink (Online service)

Other Objects (12)

Hypofractionated radiotherapy for refractory or relapsed aggressive B-cell lymphoma in the rituximab era

Hypofractionated radiotherapy for refractory or relapsed aggressive B-cell lymphoma in the rituximab era

Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma

Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma

Minimal renal toxicity after Rituximab DHAP with a modified cisplatin application scheme in patients with relapsed or refractory diffuse large B-cell lymphoma

Minimal renal toxicity after Rituximab DHAP with a modified cisplatin application scheme in patients with relapsed or refractory diffuse large B-cell lymphoma

Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study

Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study

Anti-CD20–atezolizumab–polatuzumab vedotin in relapsed/refractory follicular and diffuse large B-cell lymphoma

Anti-CD20–atezolizumab–polatuzumab vedotin in relapsed/refractory follicular and diffuse large B-cell lymphoma

Tafasitamab Plus Lenalidomide Versus 3 Rituximab-Based Treatments for Non-Transplant Eligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Matching-Adjusted Indirect Comparison

Tafasitamab Plus Lenalidomide Versus 3 Rituximab-Based Treatments for Non-Transplant Eligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Matching-Adjusted Indirect Comparison

Management of relapsed-refractory diffuse large B cell lymphoma

Management of relapsed-refractory diffuse large B cell lymphoma

Efficacy and safety of tisagenlecleucel in Japanese adult patients with relapsed/refractory diffuse large B-cell lymphoma

Efficacy and safety of tisagenlecleucel in Japanese adult patients with relapsed/refractory diffuse large B-cell lymphoma

Novel CD19-specific γ/δ TCR-T cells in relapsed or refractory diffuse large B-cell lymphoma

Novel CD19-specific γ/δ TCR-T cells in relapsed or refractory diffuse large B-cell lymphoma

The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma

The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma

Treatment Outcomes with Standard of Care in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Real-World Data Analysis

Treatment Outcomes with Standard of Care in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Real-World Data Analysis

Approximation of Long-Term Survival with Polatuzumab Vedotin Plus Bendamustine and Rituximab for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results Based on The GO29365 Trial

Approximation of Long-Term Survival with Polatuzumab Vedotin Plus Bendamustine and Rituximab for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results Based on The GO29365 Trial

Related objects